LESSONS № 1

June 28, 2024
0
0
Зміст

DRUG THERAPY OF CARDIOVASCULAR DISEASES 

 

Ischemic heart disease is the most common cardiovascular disease in developed countries, and angina pectoris is the most common condition involving tissue ischemia in which vasodilator drugs are used. The name denotes chest pain caused by accumulation of metabolites resulting from myocardial ischemia. The organic nitrates, eg, nitroglycerin,  are the mainstay of therapy for the immediate relief of angina. Another group of vasodilators, the calcium channel blockers,  is also important, especially for prophylaxis, and beta-blockers,  which are not vasodilators, are also useful in prophylaxis. Several newer groups of drugs are under investigation, including drugs that alter myocardial metabolism and selective cardiac rate inhibitors.

 Angina pectoris is a clinical syndrome characterized by episodes of chest pain. It occurs when there is a deficit in myocardial oxygen supply (myocardial ischemia) in relation to myocardial oxygen demand. It is most often caused by atherosclerotic plaque in the coronary arteries but may also be caused by coronary vasospasm. The development and progression of atherosclerotic plaque is called coronary artery disease (CAD). Atherosclerotic plaque narrows the lumen, decreases elasticity, and impairs dilation of coronary arteries. The result is impaired blood flow to the myocardium, especially with exercise or other factors that increase the cardiac workload and need for oxygen. The continuum of CAD progresses from angina to myocardial infarction. There are three main types of angina: classic angina, variant angina, and unstable angina. The Canadian Cardiovascular Society classifies clients with angina according to the amount of physical activity they can tolerate before anginal pain occurs. These categories can assist in clinical assessment and evaluation of therapy.

Опис : https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSDFkaR-xzuq1XXEH7d_UrrZGgeyYZWIbEhE5sklRsycU2JtpmejQ

Classic anginal pain is usually described as substernal chest pain of a constricting, squeezing, or suffocating nature. It may radiate to the jaw, neck, or shoulder, down the left or both arms, or to the back. The discomfort is sometimes mistaken for arthritis, or for indigestion, as the pain may be associated with nausea, vomiting, dizziness, diaphoresis, shortness of breath, or fear of impending doom. The discomfort is usually brief, typically lasting 5 minutes or less until the balance

of oxygen supply and demand is restored.

For clients at any stage of CAD development, irrespective of symptoms of myocardial ischemia, optimal management involves lifestyle changes and medications, if necessary, to control or reverse risk factors for disease progression. Risk factors are frequently additive iature and are classified as nonmodifiable and modifiable. Nonmodifiable risk factors include age, race, gender, and family history. The risk factors that can be altered include smoking, hypertension, hyperlipidemia, obesity, sedentary lifestyle, stress, and the use of drugs that increase cardiac workload (eg, adrenergics, corticosteroids).

Thus, efforts are needed to assist clients in reducing blood pressure, weight, and serum cholesterol levels, when indicated, and developing an exercise program. For clients with diabetes mellitus, glucose and blood pressure control can reduce the microvascular changes associated with the condition. In addition, clients should avoid circumstances known to precipitate acute attacks, and those who smoke should stop. Smoking is harmful to clients because:

Nicotine increases catecholamines which, in turn, increase heart rate and blood pressure.

Carboxyhemoglobin, formed from the inhalation of carbon monoxide in smoke, decreases delivery of blood and oxygen to the heart, decreases myocardial  contractility, and increases the risks of life-threatening cardiac dysrhythmias

(eg, ventricular fibrillation) during ischemic episodes.

Both nicotine and carbon monoxide increase platelet adhesiveness and aggregation, thereby promoting thrombosis.

Smoking increases the risks for myocardial infarction, sudden cardiac death, cerebrovascular disease (eg, stroke), peripheral vascular disease (eg, arterial insufficiency), and hypertension. It also reduces high-density lipoprotein, the “good” cholesterol.

Additional nonpharmacologic management strategies include surgical revascularization (eg, coronary artery bypass graft) and interventional procedures that reduce blockages (eg, percutaneous transluminal coronary angioplasty [PTCA], intracoronary stents, laser therapy, and rotoblators). However, most clients still require antianginal and other cardiovascular medications to manage their disease.

ANTIANGINAL DRUGS

Drugs used for myocardial ischemia are the organic nitrates, the beta-adrenergic blocking agents, and the calcium channel blocking agents. These drugs relieve anginal pain by reducing myocardial oxygen demand or increasing blood supply to the myocardium. Nitrates and beta blockers are described in the following sections and dosage ranges are listed in Drugs at a Glance: Nitrates and Beta Blockers. Calcium channel blockers are described in a following section; indications for use and dosage ranges are listed in Drugs at a Glance: Calcium Channel Blockers.

Опис : http://o.quizlet.com/i/DeJNmAPyscXcRDO6-3s-wg_m.jpg

Organic  nitrates  (and nitrates) are simple nitric and nitrous acid esters of alcohols. These compounds cause a rapid reduction in myocardial oxygen demand followed by rapid relief of symptoms. They are effective in stable and anstable angina, as well as Prinzmetal’s or variant angina pectoris.

 

         Nitrates, b-blockers, and calcium channel-blockers are equally effective for relief of anginal symptoms. However, for prompt relief of an ongoing attack of angina precipitated by exercise or emotional stress, sublingual (or spray form) nitroglycerin  (NITROSTAT) is the drug of choice.

         Mechanisms of action: The organic  nitrates, such as nitroglycerin, are thought to relax vascular smooth muscle by their intracellular conversion to nitrite ions and then to nitric oxide (NO), what  leads to dephosphorylation of the myosin light chain, resulting in vascular smooth muscle relaxation.

Опис : http://external.ak.fbcdn.net/safe_image.php?d=AQBGFlObGN6b3zly&url=http%3A%2F%2Fi1.ytimg.com%2Fvi%2FtpvrTozymbA%2Fmqdefault.jpg&jq=100

         At therapeutic doses, nitroglycerin has two major effects. First, it causes dilation of the large veins, resulting in pooling blood in  the veins. This diminishes preload (venous return to the heart), and reduces the work of the heart. Second, nitroglycerin dilates the coronary vasculature, providing increased blood supply to the heart muscle. Nitroglycerin causes a decrease in myocardial oxygen consumption because of decreased cardiac work.

         Pharmacokinetics. The time to onset of action varies from one minute for nitroglycerin to more than one hour for  isosorbide mononitrate. Significant first-pass metabolism of nitroglycerin occurs in the liver. Therefore, it is  common to give the drug either sublingually or via a transdermal patch.

         Adverse effects. The most common adverse effect of nitroglycerin, as well as the other nitrates, is headache. 30 to 60 % of patients receiving intermittent nitrate therapy with long-acting agents develop headaches. High doses of organic nitrates can also cause postural hypotension, facial flushing, and tachycardia.

         Tolerance to the actions of nitrates develops rapidly. It can be overcome by provision of a daily “nitrate-free interval” to restore sensitivity to the drug. This interval is typically 6 to 8, 10-12 hours, usually at night because there is decreased demand on the heart at that time. Nitroglycerin patches are worn for 12 hours and removed for 12 hours. However, Prinzmetal’s or variant angina worsens early in the morning, perhaps due to circardian catecholamine surges.  These patients nitrate-free interval should be late afternoon.

         Nitroglycerin Extended release Buccal Tablets (contain 1, 2, 2.5, 3, 5 mg of nitroglycerin). When  a buccal tablet is placed under the lipp or in the buccal pouch, it adheres to the mucosa. As the tablets gradually dissolves, it  releases nitroglycerin to the systemic circulation. Buccal nitroglycerin can be tried as a means of aborting an acute anginal attack.

Nitroglycerin tablets (NITROSTAT)is a stabilized sublingual formulation,  which contains  0,15, 0,3, 0,4, 0,6 mg of nitroglycerin. Nitroglycerin is rapidly absorbed following sublingual administration. Its onset is approximately one to three minutes. Significant pharmacologic effects are present for 30 to 60 minutes following administration by the above route. Nitroglycerin is indicated for the prophylaxis, treatment and management of patients with angina pectoris. One tablet should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack.  The dose may be repeated approximately  every five minutes until relief is obtained. If the pain persists after a total  of 3-tablets in a 15-minute period,  drug  combination should be recommended.

Nitroglycerin  (NITRO-BID) 2,5, 6,5, 9 mg capsules.  Capsules must be swollowed. Administer  the smallest  effective dose two or three times daily at 8 to 12 hours intervals. Contraindications:  acute or recent myocardial infarction, severe anemia, closed-angled glaucoma, postural hypotension, increased intracranial pressure, and idiosyncrasy to the drug.

tmp65D-2.jpg

 

Nitroglycerin injection – for intravenous use only. Must be diluted in dextrose 5 % injection, or sodium chloride (0,9 %) injection. Nitroglycerin should not be mixed with other drugs.  The concentration of the infusion solution should not exceed 400 mg/ml of nitroglycerin.

Indication and usage:

1. Control of blood pressure in perioperative hypertension:   hypertension associated with surgical procedures, especially cardiovascular procedures, such as hypertension seen during  intratracheal intubation, anesthesia, skin incision, sternotomy, cardiac bypass.

2. Congestive heart failure associated with  acute myocardial infarction.

3. Treatment of angina pectoris.

4. Production of controlled hypotension during surgical procedures.

         Nitroglycerin 2 % (NITRO-BID Ointment) (20-, 60-mg tubes) is indicated for  the treatment and prevention of angina pectoris due to coronary artery disease.  Controlled clinical trials  have demonstrated that this form of nitroglycerin is effective in improving exercise tolerance in patients with exertional angina pectoris. Clinical trials have shown significant improvement in exercise time until chest pain for up to six hours after single aplication of various doses of nitroglycerin ointment (mean doses ranged from 5 to 36 mg) to a 36-inch2 (150×150 mm) area of trunk. 

tmp659-1.jpg

 

         When applying the ointment, place the dose-determining applicator  supplied with the package printed-side down and squeeze  the necessary amount of ointment from the tube onto the applicator. Then place the applicator with the ointment-side down onto the desired area of skin, usually the chest or back.. A suggested started  dose for NITRO-BID is 7,5 mg applied to a 1×3 inch area every 8 hours. If angina pectoris  occurs while the ointment is in place, the dose should be increased, for example, to 1 inch  on a 2×3 inch area. The frequency of dosing may be also increased (eg, every 6 hours). An initiation  of therapy or change of in dosage, blood pressure (patient standing) should be monitored.

         Isosorbide dinitrate is an orally active nitrate. The drug is not readily metabolized  by the liver or smooth muscle and has lower potency thaitroglycerin in relaxing vascular smooth muscle.

 

Isosorbide dinitrate (Isordil, Sorbitrate) is used to reduce the frequency and severity of acute anginal episodes. When given sublingually or in chewable tablets, it acts in about 2 minutes, and its effects last 2 to 3 hours. When higher doses are given orally, more drug escapes metabolism in the liver and produces systemic effects in approximately 30 minutes. Therapeutic effects last about 4 hours after oral administration. The effective oral dose is usually determined by increasing the dose until headache occurs, indicating the maximum tolerable dose. Sustained-release capsules also are available.

Isosorbide mononitrate (Ismo, Imdur) is the metabolite and active component of isosorbide dinitrate. It is well absorbed after oral administration and almost 100% bioavailable. Unlike other oral nitrates, this drug is not subject to first-pass hepatic metabolism. Onset of action occurs within 1 hour, peak effects occur between 1 and 4 hours, and the elimination half-life is approximately 5 hours. It is used only for prophylaxis of angina; it does not act rapidly enough to relieve acute attacks.

The beneficial and deleterious effects of nitrate-induced vasodilation are summarized in Table 2.

Table–2 Beneficial and Deleterious Effects of Nitrates in the Treatment of Angina.

 

Effect

Result

Potential beneficial effects 

 

  Decreased ventricular volume

Decreased myocardial oxygen requirement

  Decreased arterial pressure

  Decreased ejection time

  Vasodilation of epicardial coronary arteries

Relief of coronary artery spasm

  Increased collateral flow

Improved perfusion to ischemic myocardium

  Decreased left ventricular diastolic pressure

Improved subendocardial perfusion

Potential deleterious effects 

 

  Reflex tachycardia

Increased myocardial oxygen requirement

  Reflex increase in contractility

 

  Decreased diastolic perfusion time due to tachycardia

Decreased coronary perfusion

 

Table 3 Nitrate and Nitrite Drugs Used in the Treatment of Angina.

 

Drug

Dose

Duration of Action

Short-acting 

 

 

  Nitroglycerin, sublingual

0.15–1.2 mg

10–30 minutes

  Isosorbide dinitrate, sublingual

2.5–5 mg

10–60 minutes

  Amyl nitrite, inhalant

0.18–0.3 mL

3–5 minutes

Long-acting 

 

 

  Nitroglycerin, oral sustained-action

6.5–13 mg per 6–8 hours

6–8 hours

  Nitroglycerin, 2% ointment, transdermal

1–1.5 inches per 4 hours

3–6 hours

  Nitroglycerin, slow-release, buccal

1–2 mg per 4 hours

3–6 hours

  Nitroglycerin, slow-release patch, transdermal

10–25 mg per 24 hours (one patch per day)

8–10 hours

  Isosorbide dinitrate, sublingual

2.5–10 mg per 2 hours

1.5–2 hours

  Isosorbide dinitrate, oral

10–60 mg per 4–6 hours

4–6 hours

  Isosorbide dinitrate, chewable oral

5–10 mg per 2–4 hours

2–3 hours

  Isosorbide mononitrate, oral

20 mg per 12 hours

6–10 hours

 

 

Sympathetic stimulation of beta1 receptors in the heart increases heart rate and force of myocardial contraction, both of which increase myocardial oxygen demand and may precipitate acute anginal attacks. Beta-blocking drugs prevent or inhibit sympathetic stimulation. Thus, the drugs reduce heart rate and myocardial contractility, particularly when sympathetic output is increased during exercise. A slower heart rate may improve coronary blood flow to the ischemic area. Beta blockers also reduce blood pressure, which in turn decreases myocardial workload and oxygen demand. In angina pectoris, beta-adrenergic blocking agents are used in long-term management to decrease the frequency and severity of anginal attacks, decrease the need for sublingual nitroglycerin, and increase exercise tolerance. When a beta blocker is being discontinued after prolonged use, it should be tapered in dosage and gradually discontinued or rebound angina can occur.

These drugs should not be given to clients with known or suspected coronary artery spasms because they may intensify the frequency and severity of vasospasm. This probably results from unopposed stimulation of alpha-adrenergic receptors, which causes vasoconstriction, when beta-adrenergic receptors are blocked by the drugs. Clients who continue to smoke may have reduced efficacy with the use of beta blockers. Clients with asthma should be observed for bronchospasm from blockage of beta2 receptors in the lung. Beta blockers should be used with caution in clients with diabetes mellitus because they can conceal signs of hypoglycemia except for sweating).

         The b-adrenergic blockers agents supress the activation of the heart by blocking b1 receptors. They also reduce the work of the heart by decreasing cardiac output and causing a slight decrease in blood pressure.  Propranolol is the  prototype of this class of compounds, but other b-blockers, such as metoprolol and atenolol are equally effective. Propranolol decreases  the oxygen requirement of heart muscle and therefore is effective in reducing the chest pain on exertion that is common in angina. Propranolol is therefore useful in the chronic management of stable angina (not for acute treatment). Tolerance to moderate exercise is increased and this is noticeable by improvement in the electrocardiogram. Agents with intrinsic sympathomymetic activity (for example, pindolol and acebutolol) are less effective and should be avoided. The b-blockers  reduce the frequency and severity oh angina attacks. These agents are particularly useful in the treatment of patients with myocardial infarction. The b-blockers can be used with nitrates to increase exercise duration and tolerance.  They are, however, contraindicated in patients with diabetes, peripheral vascular disease, or chronic pulmonary disease.

Propranolol is well absorbed after oral administration. It is then metabolized extensively in the liver; a relatively small  proportion of an oral dose (approximately 30%) reaches the systemic circulation. For this reason, oral doses of propranolol are much higher than IV doses. Onset of action is 30 minutes after oral administration and 1 to 2 minutes after IV injection. Because of variations in the degree of hepatic metabolism, clients vary widely in the dosages required to maintain a therapeutic response.

Atenolol, metoprolol, and nadolol have the same actions, uses, and adverse effects as propranolol, but they have long half-lives and can be given once daily. They are excreted by the kidneys, and dosage must be reduced in clients with renal

impairment.

Calcium Channel Blocking Agents

Calcium channel blockers act on contractile and conductive tissues of the heart and on vascular smooth muscle. For these cells to functioormally, the concentration of intracellular calcium must be increased. This is usually accomplished by movement of extracellular calcium ions into the cell (through calcium channels in the cell membrane) and release of bound calcium from the sarcoplasmic reticulum in the cell. Thus, calcium plays an important role in maintaining vasomotor tone, myocardial contractility, and conduction. Calcium channel blocking agents prevent the movement of extracellular calcium into the cell. As a result, coronary and peripheral arteries are dilated, myocardial contractility is decreased, and the conduction system is depressed in relation to impulse formation (automaticity) and conduction velocity.

In angina pectoris, the drugs improve the blood supply to the myocardium by dilating coronary arteries and decrease the workload of the heart by dilating peripheral arteries. In variant angina, calcium channe l blockers reduce coronary artery vasospasm. In atrial fibrillation or flutter and other supraventricular tachydysrhythmias, diltiazem and verapamil slow the rate of ventricular response. In hypertension, the drugs lower blood pressure primarily by dilating peripheral arteries.

Calcium channel blockers are well absorbed after oral administration but undergo extensive first-pass metabolism in the liver. Most of the drugs are more than 90% protein bound and reach peak plasma levels within 1 to 2 hours (6 hours or longer for sustained-release forms). Most also have short elimination half-lives (<5 hours), so doses must be given three or four times daily unless sustained-release formulations are used. Amlodipine (30 to 50 hours), bepridil (24 hours), and felodipine (11 to 16 hours) have long elimination half-lives and therefore can be given once daily. The drugs are metabolized in the liver, and dosage should be reduced in clients with severe liver disease. Dosage reductions are not required with renal disease. The calcium channel blockers approved for use in the United States vary in their chemical structures and effects on body tissues. Seven of these are chemically dihydropyridines, of which nifedipine is the prototype. Bepridil, diltiazem, and verapamil differ chemically from the dihydropyridines and each other. Nifedipine and related drugs act mainly on vascular smooth muscle to produce vasodilation, whereas verapamil and diltiazem have greater effects on the cardiac conduction system.

The drugs also vary in clinical indications for use; most are used for angina or hypertension, and only diltiazem and verapamil are used to manage supraventricular tachydysrhythmias. In clients with CAD, the drugs are effective as monotherapy but are commonly prescribed in combination with beta blockers. In addition, nimodipine is approved for use only in subarachnoid hemorrhage, in which it decreases spasm in cerebral blood vessels and limits the extent of brain damage. In animal studies, nimodipine exerted greater effects on cerebral arteries than on other arteries, probably because it is highly lipid soluble and penetrates the blood–brain barrier. Contraindications include second- or third-degree heart block, cardiogenic shock, and severe bradycardia, heart failure, or hypotension. The drugs should be used cautiously with milder bradycardia, heart failure, or hypotension and with renal or hepatic impairment.

 


 

         The calcium channel blockers inhibit the entrance of calcium into cardiac and smooth muscle cells of the coronary and systemic arterial beds. All calcium channel blockers are therefore vasodilators that cause a decrease in smooth muscle tone and vascular resistance. At clinical doses, these agents affect primarily the resistance of vascular smooth muscle and the myocardium. [Note: Verapamil mainly affects the myocardium, whereas nifedipine exertrs a greater effect on smooth muscle in the peripheral vasculature. Diltiazem is intermediate inits actions].

         Nifedipine (adalat) – 10, 20 mg capsules –  functions mainly as an arteriolar vasodilator. This drug has minimal effect on cardiac conduction or heart rate. Nifedipine is administered orally and has a short life (about 4 hours) requiring multiple dosing. The vasodilation effect of nifedipine is useful in the treatment of variant angina caused by spontaneous coronary spasm.

         Therapy should be initiated with 19 mg capsule. The starting dose is one 10 mg calsule, swallowed whole, 3 times/day. The usual effective dose range is 10 20 mg three times daily. Doses of 20-30 mg three or four times daily may be effective in patients with evidence of coronary  artery spasm. More than 180 mg per day is not recommended. Nifedipine titration should proceed over a 7-14 day period. A single dose should rarely exceed 30 mg.

Nifedipine  can cause flushing, headeache, hypotension, and peripheral edema as side effects of its vasodilation activity. The drug may cause reflex tachycardia if peripheral vasodilation is marked resulting in a substantial decrease in blood pressure.

         Verapamil slows cardiac conduction directly and thus decreases heart rate and oxygen demand. Verapamil causes greater negative inotropic effects than does nifedipine, but it is a weaker vasodilator. Verapamil is contraindicated in patients with preexisting depressed cardiac function or AV condunction abnormalities. It is also causes constipation. Verapamil should be used with caution in digitalized patients, since it increases digoxin levels.

         Diltiazem has  cardiovascular effects thah are similar to those of verapamil. It reducws the heart rate, although to a lesser extent than verapamil, and also decreases blood pressure. In addition, diltiazem can relieve coronary artery spasm and is therefore particularly useful in patients with variant angina. The incidence of adverse side effects is low.

Clinical Pharmacology of Some Calcium Channel-Blocking Drugs

 

Drug

Oral Bioavailability (%)

Half-life (hours)

Indication

Dosage

Dihydropyridines 

 

 

 

 

  Amlodipine

65–90

30–50

Angina, hypertension

5–10 mg orally once daily

  Felodipine

15–20

11–16

Hypertension, Raynaud’s phenomenon

5–10 mg orally once daily

  Isradipine

15–25

8

Hypertension

2.5–10 mg orally twice daily

  Nicardipine

35

2–4

Angina, hypertension

20–40 mg orally every 8 hours

  Nifedipine

45–70

4

Angina, hypertension, Raynaud’s phenomenon

3–10 mcg/kg IV; 20–40 mg orally every 8 hours

  Nimodipine

13

1–2

Subarachnoid hemorrhage

40 mg orally every 4 hours

  Nisoldipine

< 10

6–12

Hypertension

20–40 mg orally once daily

  Nitrendipine

10–30

5–12

Investigational

20 mg orally once or twice daily

Miscellaneous 

 

 

 

 

  Diltiazem

40–65

3–4

Angina, hypertension, Raynaud’s phenomenon

75–150 mcg/kg IV; 30–80 mg orally every 6 hours

  Verapamil

20–35

6

Angina, hypertension, arrhythmias, migraine

75–150 mcg/kg IV; 80–160 mg orally every 8 hours

 

Adjunctive Antianginal Drugs

 

In addition to antianginal drugs, several other drugs may be used to control risk factors and prevent progression of myocardial ischemia to myocardial infarction and sudden cardiac death. These may include:

Aspirin. This drug has become the standard of care because of its antiplatelet (ie, antithrombotic) effects. Recommended doses vary from 81 mg daily to 325 mg daily or every other day; apparently all doses are beneficial in reducing the possibility of myocardial reinfarction, stroke, and death. Clopidogrel, 75 mg/day,

is an acceptable alternative for individuals with aspirin allergy.

Antilipemics. These drugs may be needed by clients who are unable to lower serum cholesterol levels sufficiently with a low-fat diet. Lovastatin or a related “statin” is often used. The goal is usually to reduce the serum cholesterol level below 200 mg/dL and lowdensity lipoprotein cholesterol to below 130 mg/dL.

Antihypertensives. These drugs  may be needed for clients with hypertension. Because beta blockers and calcium channel blockers are used to manage hypertension as well as angina, one of these drugs may be effective for both disorders.

PRINCIPLES OF THERAPY

Goals of Therapy

The goals of drug therapy are to relieve acute anginal pain; reduce the number and severity of acute anginal attacks; improve exercise tolerance and quality of life; delay progression of CAD; prevent myocardial infarction; and prevent sudden cardiac death.

Choice of Drug and Dosage Form

For relief of acute angina and prophylaxis before events that cause acute angina, nitroglycerin (sublingual tablets or translingual spray) is usually the primary drug of choice. Sublingual or chewable tablets of isosorbide dinitrate also may be used. For long-term prevention or management of recurrent angina, oral or topical nitrates, beta-adrenergic blocking agents, or calcium channel blocking agents are used.

Combination drug therapy with a nitrate and one of the other drugs is common and effective. Clients taking one or more long-acting antianginal drugs should carry a short-acting drug as well, to be used for acute attacks.

 

Titration of Dosage

Dosage of all antianginal drugs should be individualized to achieve optimal benefit and minimal adverse effects. This is usually accomplished by starting with relatively small doses and increasing them at appropriate intervals as necessary. Doses may vary widely among individuals.

 

Tolerance to Long-Acting Nitrates

 

Clients who take long-acting dosage forms of nitrates on a regular schedule develop tolerance to the vasodilating (antianginal) effects of the drug. The clients more likely to develop tolerance are those on high-dose, uninterrupted therapy. Although tolerance decreases the adverse effects of hypotension, dizziness, and headache, therapeutic effects also may be decreased. As a result, episodes of chest pain may occur more often or be more severe than expected. In addition, shortacting nitrates may be less effective in relieving acute pain. Opinions seem divided about the best way to prevent or manage nitrate tolerance. Some authorities recommend using short-acting nitrates wheeeded and avoiding the long-acting forms. Others recommend using the long-acting forms for 12 to 16 hours daily during active periods and omitting them during inactive periods or sleep.

Thus, a dose of an oral nitrate or topical ointment would be given every 6 hours for three doses daily, allowing a rest period of 6 hours without a dose. Transdermal discs should be removed at bedtime. If anginal symptoms occur during sleeping hours, short-acting nitrates may be beneficial in relieving the symptoms. All nitrates should be administered at the lowest effective dosage.

 

Use in Children

The safety and effectiveness of antianginal drugs have not been established for children. Nitroglycerin has been given IV for heart failure and intraoperative control of blood pressure, with the initial dose adjusted for weight and later doses titrated to response.

 

Use in Older Adults

Antianginal drugs are often used because cardiovascular disease and myocardial ischemia are common problems in older adults. Adverse drug effects, such as hypotension and syncope, are likely to occur, and they may be more severe than in younger adults. Blood pressure and ability to ambulate safely should be closely monitored, especially when drug therapy is started or dosages are increased. Ambulatory clients also should be monitored for their ability to take the drugs correctly.

With calcium channel blockers, older adults may have higher plasma concentrations of verapamil, diltiazem, nifedipine, and amlodipine. This is attributed to decreased hepatic metabolism of the drugs, probably because of decreased hepatic blood flow. In addition, older adults may experience more hypotension with verapamil, nifedipine, and felodipine than younger clients. Blood pressure should be monitored with these drugs.

Use in Renal Impairment

Little information is available about the use of antianginal drugs in clients with impaired renal function. A few studies indicate that advanced renal failure may alter the pharmacokinetics of calcium channel blockers. Although the pharmacokinetics of diltiazem and verapamil are quite similar in clients with normal and impaired renal function, caution is still advised. With verapamil, about 70% of a dose is excreted as metabolites in urine.

Dosage reductions are considered unnecessary with verapamil and diltiazem but may be needed with nifedipine and several other dihydropyridine derivatives. With nifedipine, protein binding is decreased and the elimination half-life is prolonged with renal impairment. In a few clients, reversible elevations in blood urea nitrogen and serum creatinine have occurred. With nicardipine, plasma concentrations are higher in clients with renal impairment, and dosage should be reduced. Bepridil should be used with caution because its metabolites are excreted mainly in urine.

 

Use in Hepatic Impairment

Nitrates, beta blockers, and calcium channel blockers are metabolized in the liver, and all should be used with caution in clients with significant impairment of hepatic function from reduced blood flow or disease processes.

With oral nitrates, it is difficult to predict effects. On the one hand, first-pass metabolism is reduced, which increases bioavailability (amount of active drug) of a given dose. On the other hand, the nitrate reductase enzymes that normally deactivate the drug may increase if large doses are given. In this case, more enzymes are available and the drug is metabolized more rapidly, possibly reducing therapeutic effects of a given dose. Relatively large doses of oral nitrates are sometimes given to counteract the drug tolerance (reduced hemodynamic effects) associated with chronic use. In addition, metabolism of nitroglycerin and isosorbide dinitrate normally produces active metabolites. Thus, if metabolism is reduced by liver impairment, drug effects may be decreased and shorter in duration.

With calcium channel blockers, impairment of liver function has profound effects on the pharmacokinetics and pharmacodynamics of most of these drugs. Thus, the drugs should be used with caution, dosages should be substantially reduced, and clients should be closely monitored for drug effects (including periodic measurements of liver enzymes). These recommendations stem from the following effects:

An impaired liver produces fewer drug-binding plasma proteins such as albumin. This means that a greater proportion of a given dose is unbound and therefore active.

In clients with cirrhosis, bioavailability of oral drugs is greatly increased and metabolism (of both oral and parenteral drugs) is greatly decreased. Both of these effects increase plasma levels of drug from a given dose (essentially an overdose). The effects result from shunting of blood around the liver so that drug molecules circulating in the bloodstream do not come in contact with drug-metabolizing enzymes and therefore are not metabolized. For example, the bioavailability of verapamil, nifedipine, felodipine, and nisoldipine is approximately double and their clearance is approximately one third that of clients without cirrhosis.

Although hepatotoxicity is uncommon, clinical symptoms of hepatitis, cholestasis, or jaundice and elevated liver enzymes (eg, alkaline phosphatase, creatine kinase [CK], lactate dehydrogenase [LDH], aspartate aminotransferase [AST], alanine aminotransferase [ALT]) have occurred, mainly with diltiazem, nifedipine, and verapamil. These changes resolve if the causative drug is stopped.

 

Use in Critical Illness

Antianginal drugs have multiple cardiovascular effects and may be used alone or in combination with other cardiovascular drugs in clients with critical illness. They are probably used most often to manage severe angina, severe hypertension, or serious cardiac dysrhythmias. For example, IV nitroglycerin may be used for angina and hypertension; an IV beta blocker or calcium channel blocker may be used to improve cardiovascular function with angina, hypertens ion, or supraventricular tachydysrhythmias. With any of these drugs, dosage must be carefully titrated and clients must be closely monitored for hypotension and other drug effects.

In addition, absorption of oral drugs or topical forms of nitroglycerin may be impaired in clients with extensive edema, heart failure, hypotension, or other conditions that impair blood flow to the gastrointestinal tract or skin.

 


CARDIAC DYSRHYTHMIAS

Cardiac arrhythmias are a common problem in clinical practice, occurring in up to 25% of patients treated with digitalis, 50% of anesthetized patients, and over 80% of patients with acute myocardial infarction. Arrhythmias may require treatment because rhythms that are too rapid, too slow, or asynchronous can reduce cardiac output. Some arrhythmias can precipitate more serious or even lethal rhythm disturbances; for example, early premature ventricular depolarizations can precipitate ventricular fibrillation. In such patients, antiarrhythmic drugs may be precipitate ventricular fibrillation. In such patients, antiarrhythmic drugs may be lifesaving. On the other hand, the hazards of antiarrhythmic drugs—and in particular the fact that they can precipitate lethal arrhythmias in some patients—has led to a reevaluation of their relative risks and benefits. In general, treatment of asymptomatic or minimally symptomatic arrhythmias should be avoided for this reason.

Cardiac dysrhythmias can originate in any part of the conduction system or from atrial or ventricular muscle. They result from disturbances in electrical impulse formation (automaticity), conduction (conductivity), or both. The characteristic of automaticity allows myocardial cells other than the SA node to depolarize and initiate the electrical impulse that culminates in atrial and ventricular contraction. This may occur when the SA node fails to initiate an impulse or does so too slowly. When the electrical impulse arises anywhere other than the SA node, it is an abnormal or ectopic focus. If the ectopic focus depolarizes at a rate faster than the SA node, the ectopic focus becomes the dominant pacemaker. Ectopic pacemakers may arise in the atria, AV node, Purkinje fibers, or ventricular muscle. They may be activated by hypoxia, ischemia, or hypokalemia. Ectopic foci indicate myocardial irritability (increased responsiveness to stimuli) and potentially serious impairment of cardiac function.

 

 

A common mechanism by which abnormal conduction causes dysrhythmias is called reentry excitation. During normal conduction, the electrical impulse moves freely down the conduction system until it reaches recently excited tissue that is refractory to stimulation. This causes the impulse to be extinguished. The SA node then recovers, fires spontaneously, and the conduction process starts over again. Reentry excitation means that an impulse continues to reenter an area of the heart rather than becoming extinguished. For this to occur, the impulse must encounter an obstacle in the normal conducting pathway. The obstacle is usually an area of damage, such as myocardial infarction. The damaged area allows conduction in only one direction and causes a circular movement of the impulse.

Dysrhythmias may be mild or severe, acute or chronic, episodic or relatively continuous. They are clinically significant if they interfere with cardiac function (ie, the heart’s abil-ity to pump sufficient blood to body tissues). The normal heartcan maintain an adequate cardiac output with ventricular rates ranging from 40 to 180 beats per minute. The diseased heart, however, may not be able to maintain an adequate cardiac output with heart rates below 60 or above 120. Dysrhythmias are usually categorized by rate, location, or patterns of conduction.

BRADYCARDIAS AND HEART BLOCK

Bradycardias may be due to failure of impulse formation (sinus bradycardia) or failure of impulse conduction from the atria to the ventricles (atrioventricular block).

Bradycardia

Sinus bradycardia

Sinus bradycardia is due to extrinsic factors influencing a relatively normal sinus node or due to intrinsic sinus node disease. The mechanism can be acute and reversible or chronic and degenerative. Common causes of sinus bradycardia

include:

Extrinsic causes

■ hypothermia, hypothyroidism, cholestatic jaundice and raised intracranial pressure

■ drug therapy with beta-blockers, digitalis and other antiarrhythmic drugs

■ neurally mediated syndromes.

Intrinsic causes

■ acute ischaemia and infarction of the sinus node (as a complication of acute myocardial infarction)

■ chronic degenerative changes such as fibrosis of the atrium and sinus node (sick sinus syndrome).

Sick sinus syndrome or sinoatrial disease is usually caused by idiopathic fibrosis of the sinus node. Other causes of fibrosis such as ischaemic heart disease, cardiomyopathy or myocarditis can also cause the syndrome. Patients develop episodes of sinus bradycardia or sinus arrest and commonly, owing to diffuse atrial disease, experience paroxysmal atrial tachyarrhythmias (tachy-bradysyndrome).

Neurally mediated syndromes

Neurally mediated syndromes are due to a reflex (called Bezold–Jarisch) that may result in both bradycardia (sinus bradycardia, sinus arrest and AV block) and reflex peripheral vasodilatation. These syndromes usually present as syncope or pre-syncope (dizzy spells).

Carotid sinus syndrome occurs in the elderly and mainly results in bradycardia. Syncope occurs.

Neurocardiogenic (vasovagal) syncope (syndrome) usually presents in young adults but may present for the first time in elderly patients. It results from a variety of situations (physical and emotional) that affect the autonomic nervous system. The efferent output may be predominantly bradycardic, predominantly vasodilatory or mixed.

Postural orthostatic tachycardia syndrome (POTS) is a sudden and significant increase in heart rate associated with normal or mildly reduced blood pressure produced by standing.

The underlying mechanism is a failure of the peripheral vasculature to appropriately constrict in response to orthostatic stress, which is compensated by an excessive increase in heart rate.

Many medications, such as antihypertensives, tricyclic antidepressants and neuroleptics can be the cause of syncope, particularly in the elderly. Careful dose titration and avoidance of combining two agents with potential to cause syncope help to prevent iatrogenic syncope.

Treatment

The management of sinus bradycardia is first to identify and if possible remove any extrinsic causes. Temporary pacing may be employed in patients with reversible causes until a normal sinus rate is restored and in patients with chronic degenerative conditions until a permanent pacemaker is implanted.

Chronic symptomatic sick sinus syndrome requires permanent pacing (DDD), with additional antiarrhythmic drugs (or ablation therapy) to manage any tachycardia element. Thromboembolism is common in tachy-brady syndrome and patients should be anticoagulated unless there is a contraindication. Patients with carotid sinus hypersensitivity (asystole > 3 s), especially if symptoms are reproduced by carotid sinus massage, and in whom life-threatening causes of syncope have been excluded, benefit from pacemaker implantation. Treatment options in vasovagal attacks include avoidance, if possible, of situations known to cause syncope in a particular patient. Increased salt intake, compression of the lower legs with hose and drugs such as beta-blockers, alpha-agonists or myocardial negative inotropes (such as disopyramide) may be helpful. In selected patients with ‘malignant’ neurocardiogenic syncope (syncope associated with injuries) permanent pacemaker therapy is helpful. These patients benefit from dual chamber pacemakers with a feature called ‘rate drop response’ which, once activated, paces the heart at a fast rate for a set period of time in order to prevent syncope.

Heart block

Heart block or conduction block may occur at any level in the conducting system. Block in either the AV node or the His bundle results in AV block, whereas block lower in the conduction system produces bundle branch block.

Atrioventricular block

There are three forms:

First-degree AV block

This is simple prolongation of the PR interval to more than 0.22 s. Every atrial depolarization is followed by conduction to the ventricles but with delay (Fig.).

An ECG showing first-degree atrioventricular block with a prolonged PR interval. In this trace coincidental ST depression is also present.

Three varieties of seconddegree atrioventricular (AV) block. (a) Wenckebach (Mobitz type I) AV block. The PR interval gradually prolongs until the P wave does not conduct to the ventricles (arrows). (b) Mobitz type II AV block. The P waves that do not conduct to the ventricles (arrows) are not preceded by gradual PR interval prolongation. (c) Two P waves to each QRS complex. The PR interval prior to the dropped P wave is always the same. It is not possible to define this type of AV block as type I or type II Mobitz block and it is, therefore, a third variety of second-degree AV block (arrows show P waves).

Two examples of complete heart block. (a) Congenital complete heart block. The QRS complex is narrow (0.08 s) and the QRS rate is relatively rapid (52 b.p.m.). (b) Acquired complete heart block. The QRS complex is broad (0.13 s) and the QRS rate is relatively slow (38 b.p.m.).

Second-degree AV block

This occurs when some P waves conduct and others do not.

There are several forms (Fig.):

■ Mobitz I block (Wenckebach block phenomenon) is progressive PR interval prolongation until a P wave fails to conduct. The PR interval before the blocked P wave is much longer than the PR interval after the blocked P wave.

■ Mobitz II block occurs when a dropped QRS complex is not preceded by progressive PR interval prolongation. Usually the QRS complex is wide (> 0.12 s). Usually the QRS complex is wide (> 0.12 s).

■ 2 : 1 or 3 : 1 (advanced) block occurs when every second or third P wave conducts to the ventricles. This form of second-degree block is neither Mobitz I nor II. Wenckebach AV block in general is due to block in the AV node, whereas Mobitz II block signifies block at an infranodal level such as the His bundle. The risk of progression to complete heart block is greater and the reliability of the resultant escape rhythm is less with Mobitz II block. Therefore pacing is usually indicated in Mobitz II block, whereas patients with Wenckebach AV block are usually monitored. Acute myocardial infarction may produce second-degree heart block. In inferior myocardial infarction, close monitoring and transcutaneous temporary back-up pacing are all that is required. In anterior myocardial infarction, second-degree heart block is associated with a high risk of progression to complete heart block, and temporary pacing followed by permanent pacemaker implantation is usually indicated. 2 : 1 Heart block may either be due to block in the AV node or at an infra-nodal level. Management depends on the clinical setting in which it occurs.

Third-degree (complete) AV block

Complete heart block occurs when all atrial activity fails to conduct to the ventricles (Fig.). In patients with complete heart block the aetiology needs to be established. In this situation life is maintained by a spontaneous escape rhythm.

Narrow complex escape rhythm (< 0.12 s QRS complex) implies that it originates in the His bundle and therefore that the region of block lies more proximally in the AV node. The escape rhythm occurs with an adequate rate (50–60 b.p.m.) and is relatively reliable.

Treatment depends on the aetiology. Recent-onset narrow-complex AV block due to transient causes may respond to intravenous atropine, but temporary pacing facilities should be available for the management of these patients. Chronic narrow-complex AV block requires permanent pacing (dual chamber) if it is symptomatic or associated with heart disease. Pacing is also advocated for isolated,

congenital AV block, even if asymptomatic. Broad complex escape rhythm (> 0.12 s) implies that the escape rhythm originates below the His bundle and therefore that the region of block lies more distally in the His–Purkinje system.

The resulting rhythm is slow (15–40 b.p.m.) and relatively unreliable. Dizziness and blackouts (Stokes–Adams attacks) often occur. In the elderly, it is usually caused by degenerative fibrosis and calcification of the distal conduction system (Lev’s disease). In younger individuals, a proximal progressive cardiac conduction disease due to the inflammatory process is known as Lenegre’s syndrome. Sodium channel abnormalities have been identified in both syndromes. Broad-complex AV block may also be caused by ischaemic heart disease, myocarditis or cardiomyopathy. Permanent pacemaker implantation is indicated, as pacing considerably reduces the mortality. Because ventricular arrhythmias are not uncommon, an implantable cardioverter–defibrillator (ICD) may be indicated in those with severe left ventricular dysfunction (> 0.30 s).

 

Antiarrhythmic agents

 

Antidysrhythmic agents are diverse drugs used for prevention and management of cardiac dysrhythmias. Dysrhythmias, also called arrhythmias, are abnormalities in heart rate or rhythm. They become significant when they interfere with cardiac function and ability to perfuse body tissues. To aid in understanding of dysrhythmias and antidysrhythmic drug therapy, the physiology of cardiac conduction and contractility is reviewed.

 


Effects of drugs on automaticity:  Most of antiarrhythmic agents suppress automaticity (1) by decreasing the slope of diastolic depolarization  and/or by raising the  threshold of discharge to a less negative voltage. Such drugs cause the frequency of discharge to decrease, an effect that is more pronounced  in cells with ectopic pacemaker activity than iormal cells.

Indications for Use

Antidysrhythmic drug therapy commonly is indicated in the following conditions:

1. To convert atrial fibrillation (AF) or flutter to normalsinus rhythm (NSR)

2. To maintain NSR after conversion from AF or flutter

3. When the ventricular rate is so fast or irregular that cardiac output is impaired. Decreased cardiac output leads to symptoms of decreased systemic, cerebral, and coronary circulation.

4. When dangerous dysrhythmias occur and may be fatal if not quickly terminated. For example, ventricular tachycardia may cause cardiac arrest.

 

         Effects of drugs on conduction abnormalities: Antiarrhythmic agents prevent reentry by slowing conduction and/or  increasing the refractory period to convent a unidirectional block into a bidirectional block.

         As noted above, the antiarrhythmic drugs can  modify  impulse generation and conduction. More than a dozen such drugs  that are patentially  usefull in treating arrhythmias  are currently available.  However, only a limited number of these agents  are clinically  beneficial in the treatment of selected arrhythmias. For example, the acute termination  of ventricular tachycardia by lidocaine or supraventricular tachycardia by adenosine  or verapamil are  examples in which antiarrhythmic therapy results in decreased morbidity. In contrast, many of the antiarrhythmic agents are now known to have lethal proarrhythmic actions, that is, to cause arrhythmias.

         The antiarrhythmic drugs can be classified according to their  predominant effects on the action potential.  Although this classification is convenient, it is not entirely clear-cut, because many of the drugs have actions relating to more than one class or they have active metabolites with a different class of action.

        

 

Classification of antiarrhythmic drugs

 

CLASS

Mechanism of Action

Drug name

IA

Na+Channel blocker

Disopyramide, procainamide, quinidine

IB

Na+Channel blocker

Lidocaine, mexiletine, tocainide

IC

Na+Channel blocker

Flecainide, propafenone

II

b Adrenoreceptor blocker

Esmolol, metoprolol, pindolol, propranolol

III

K+Channel blocker

Amiodarone, bretylium, sotalol

IV

Ca++ Channel blocker

Diltiazem, verapamil

Other antiarrhythmic drugs

Adenosine, digoxin

 

 

Therapeutic indications for some commonly encountered arrhythmias

Type of arrhythmia

Class I

Class II

Class III

Class IV

Other

ATRIAL ARRHYTHMIAS

Atrial flutter

 

 

 

 

 

Commonly used drugs

 

Propranolol

 

Verapamil

 

Alternative drugs

Quinidine

 

 

 

Digoxin

Atrial fibrillation

 

 

 

 

 

Commonly used drugs

 

Propranolol

 

 

Anticoagulant therapy

Alternative drugs

Quinidine

 

Amiodarone

 

 

SUPRAVENTRICULAR TACHYCARDIAS

AV nodal reentry

 

 

 

 

 

Commonly used drugs

 

Propranolol

 

Verapamil

 

Alternative drugs

 

 

 

 

Digoxin

Acute  supraventricular tachycardia

 

 

 

 

 

Commonly used drugs

 

 

 

 

Adenosine

Alternative drugs

 

 

 

Verapamil

 

VENTRICULAR TACHYCARDIAS

Acute  ventricular tachycardia

 

 

 

 

 

Commonly used drugs

Lidocaine

 

 

 

 

Alternative drugs

 

 

Sotalol, amiodarone

 

 

Ventricular  fibrillation (not responding to electrical defibrillation)

 

 

 

 

 

Commonly used drugs

 

 

 

 

Epinephrine

Alternative drugs

Lidocaine

 

Bretylium, amiodarone

 

 

 

HYPERTENSION

Hypertension is persistently high blood pressure that results from abnormalities in regulatory mechanisms. It is usually defined as a systolic pressure above 140 mm Hg or a diastolic pressure above 90 mm Hg on multiple blood pressure measurements.

 

Primary or essential hypertension (that for which no cause can be found) makes up 90% to 95% of known cases. Secondary hypertension may result from renal, endocrine, or central nervous system disorders and from drugs that stimulate the SNS or cause retention of sodium and water. Primary hypertension can be controlled with appropriate therapy; secondary hypertension can sometimes be cured by surgical therapy.

The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, published in 1997, classified blood pressures in adults (in mm of Hg), as follows:

Normal = systolic 130 or below; diastolic 85 or below

High normal = systolic 130 to 139; diastolic 85 to 89

Stage 1 hypertension (mild) = systolic 140 to 159; diastolic

90 to 99

Stage 2 hypertension (moderate) = systolic 160 to 179;

diastolic 100 to 109

Stage 3 hypertension (severe) = systolic 180 to 209; diastolic

110 to 119

Stage 4 hypertension (very severe) = systolic 210 or above; diastolic 120 or above

A systolic pressure of 140 or above with a diastolic pressure below 90 is called isolated systolic hypertension and is more common in the elderly.

Hypertension profoundly alters cardiovascular function by increasing the workload of the heart and causing thickening and sclerosis of arterial walls. As a result of increased cardiac workload, the myocardium hypertrophies as a compensatory mechanism and heart failure eventually occurs. As a result of endothelial dysfunction and arterial changes (vascular remodeling), the arterial lumen is narrowed, blood supply to tissues is decreased, and risks of thrombosis are increased. In addition, necrotic areas may develop in arteries, and these may rupture with sustained high blood pressure. The areas of most serious damage are the heart, brain, kidneys, and eyes. These are often called target organs.

Initially and perhaps for years, primary hypertension may produce no symptoms. If symptoms occur, they are usually vague and nonspecific. Hypertension may go undetected, undetected, or it may be incidentally discovered when blood pressure measurements are taken as part of a routine physical examination, screening test, or assessment of other disorders. Eventually, symptoms reflect target organ damage.

Hypertension is often discovered after a person experiences angina pectoris, myocardial infarction, heart failure, stroke, or renal disease. Hypertensive emergencies are episodes of severely elevated blood pressure that may be an extension of malignant (rapidly progressive) hypertension or caused by cerebral hemorrhage, dissecting aortic aneurysm, renal disease, pheochromocytoma, or eclampsia. These require immediate management, usually intravenous (IV) antihypertensive drugs, to lower blood pressure. Symptoms include severe headache, nausea, vomiting, visual disturbances, neurologic disturbances, disorientation, and decreased level of consciousness (drowsiness, stupor, coma). Hypertensive urgencies are episodes of less severe hypertension and are often managed with oral drugs. The goal of management is to lower blood pressure within 24 hours. In most instances, it is better to lower blood pressure gradually and to avoid wide fluctuations in blood pressure.

 

Mild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected  to minimize adverse effects  of the combined regimen.  Treatment is initiated  with any of four drugs depending on the individual  patient: a diuretic, a b-blocker, an ACE inhibitor, or a calcium channel blocker.  If blood pressure is inadequately controlled, a second drug is added.  A b-blocker is usually added if the initial drug was a diuretic, or a diuretic is added if the first drug was a b-blocker. A vasodilator can be added as a third step for those patients who still fail to respond.

Certain  subsets of the hypertensive population respond better to one class of drug  than another. For example, black patients respond well to diuretics and calcium channel blockers, but therapy with b-blockers or ACE inhibitors is often less effective. Similarly, calcium channel blockers, ACE inhibitors, and diuretics are favored for treatment of hypertension in the elderly, whereas b-blockers and a-antagonists are less well tolerated. Furthermore, hypertension  may coexist with other diseases that can be aggravated by some of the antihypertensive drugs.

 

ANTIHYPERTENSIVE DRUGS

Drugs used in the management of primary hypertension belong to several different groups, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), also called angiotensin II receptor antagonists (AIIRAs), antiadrenergics, calcium channel blockers, diuretics, and direct vasodilators. In general, these drugs act to decrease blood pressure by decreasing cardiac output or peripheral vascular resistance.

 

 

 

I. DIURETICS

Bumetanide, furosemide, hydrochlorthiazide, spironolactone, triamterene

 II. b-BLOCKERS

Atenolol, labetalol, metoprolol, propranolol, timolol

III. ACE  INHIBITORS

Captopril, benazepril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril

IV. ANGIOTENSIN II ANTAGONIST

Losartan

V. Ca++CHANNEL BLOCKERS

Amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, verapamil

VI. a-BLOCKERS

Doxazosin, prazosin,  terazosin

VII. OTHER

Clonidine, diazoxide, hydralazine, a-methyldopa, minoxidil, sodium nitroprusside

 

 

Treatment of hypertension  in patients with concomitant diseases

 

CONCOMITANT DISEASE

DRUGS COMMONLY USED IN TREATING HYPERTENSION

Angina pectoris

 

 

 

 

Commonly used drugs

 

b-Blockers

 

Ca++ Channel blockers

Alternative drugs

diuretics

 

ACE inhibitors

 

Diabetes (insulin-dependent)

 

 

 

Commonly used drugs

 

 

ACE inhibitors

Ca++ Channel blockers

 

Alternative drugs

 

 

 

 

Hyperlipidemia

 

 

 

 

Commonly used drugs

 

 

ACE inhibitors

Ca++ Channel blockers

 

Alternative drugs

 

 

 

 

Congestive heart failure

 

 

 

Commonly used drugs

diuretics

 

ACE inhibitors

 

Alternative drugs

 

 

 

Avoid verapamil

Previous myocardial infarction

 

 

 

Commonly used drugs

 

b-Blockers

ACE inhibitors

 

Alternative drugs

diuretics

 

 

Ca++ Channel blockers

Chronic renal disease

 

 

 

Commonly used drugs

diuretics

 

 

Ca++ Channel blockers

Alternative drugs

 

b-Blockers

ACE inhibitors

 

Asthma, chronic pulmonary  disease

 

 

 

Commonly used drugs

diuretics

 

 

Ca++ Channel blockers

Alternative drugs

 

 

ACE inhibitors

 

 

DIURETICS and/or b-Blockers are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Recent data suggest that diuretics  are superior to b-Blockers in older adults.

 

 

 

 Antihypertensive effects of diuretics are usually attributed to sodium and water depletion. In fact, diuretics usually produce the same effects as severe dietary sodium restriction. In many cases of hypertension, diuretic therapy alone may lower blood pressure. When diuretic therapy is begun, blood volume and cardiac output decrease. With long-term administration of a diuretic, cardiac output returns to normal, but there is a persistent decrease in peripheral vascular resistance. This has been attributed to a persistent small reduction in extracellular water and plasma volume, decreased receptor sensitivity to vasopressor substances such as angiotensin, direct arteriolar vasodilation, and arteriolar vasodilation secondary to electrolyte depletion in the vessel wall.

In moderate or severe hypertension that does not respond to a diuretic alone, the diuretic may be continued and another antihypertensive drug added, or monotherapy with a different type of antihypertensive drug may be tried.

 

  Thiazide diuretics. All oral diuretics are effective in the treatment of hypertension, but the thiazides have the most widespread use.  Thiazides,  such as hydochlorothiazide, lower blood  pressure , initially by increasing sodium and water excretion. This causes a decrease in  extracellular volume , resulting  in a decrease in cardiac output and renal  blood flow. With long term treatment, plasma volume approaches a normal value, but peripheral resistance decreases.  Spironolactone, a potassium-sparing diuretic, is often used with thiazides.

Thiazide diuretics are usefull  in combination therapy  with a variety  of other antihypertensive agents including b-blockers and ACE inhibitors. Thiazides are particularly useful in the treatment of black  or elderly patients, and in those with chronic renal disease. Thiazides are not effective in patients with inadequate kidney function (creatinine clearance less than 50 mls/min). Loop diretics may be required in these patients.

Adverse effects: Thiazide diuretics induce hypokalemia and hyperuricemia in 70 % of patients, and hyperglycemia in 10 % of patients.  Serum potassium levels should be monitored  closely on patients who are predisposed to cardiac arrhythmias (with left ventricular hypertrophy, ischemic heart disease, or chronic congestive heart failure) (to prevent development of fatigue, cramps, and arrhythmias) and who are concurrently being treated with both thiazide diuretics and digitalis glycosides.   Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia.

 

     The loop  diuretics act promptly, even in patients who have poor renal function or who have not responded to thiazides or other diuretics.

b-ADRENOCEPTOR BLOCKING AGENTS – reduce blood pressure primarily by decreasing cardiac output.  They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys.  The prototype b-blocker is propranolol, which acts at both b1 and  b2 receptors. Newer agents, such as atenolol, metoprolol, bisoprolol, are selective for b1 receptors. These agents  are commonly used in disease states such as asthma, in which propranolol is contraindicated. 

 

The b-blockers are more effective for treating hypertension in white young patients.  They are useful in treating conditions that may coexist  with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, glaucoma, and migraine headache.

The b-blockers are orally active. The b-blockers may take several weeks to develop their full effects.

Adverse effects. The b-blockers may cause  CNS side effects such as fatigue, lethargy, insomnia, hypotension, and hallucinations; they may decrease libido and cause impotence; drug-induced sexual  dysfunction can severly reduce patient compliance.  The b-blockers may disturb lipid metabolism, decreasing high-density lipoproteins and increasing plasma triacylglycerol.

Drug withdrawal: Abrupt  withdrawal may cause rebound hypertension, probably as a result of up-regulation on b-receptors.  Patients should be taped off of b-blocker therapy  in order to avoid precipitation of arrhythmias. The  b-blockers should be avoided in treating patients with asthma, congestive heart failure, and peripheral vascular disease.

                  

                            ACE-INHIBITORS.

Angiotensin-converting enzyme (also called kininase) is mainly located in the endothelial lining of blood vessels, which is the site of production of most angiotensin II. This same enzyme also metabolizes bradykinin, an endogenous substance with strong vasodilating properties. ACE inhibitors block the enzyme that normally converts angiotensin I to the potent vasoconstrictor angiotensin II. By blocking production of angiotensin II, the drugs decrease vasoconstriction (having a vasodilating effect) and decrease aldosterone production (reducing retention of sodium and water). In addition to inhibiting formation of angiotensin II, the drugs also inhibit the breakdown of bradykinin, prolonging its vasodilating effects. These effects and possibly others help to prevent or reverse the remodeling of heart muscle and blood vessel walls that impairs cardiovascular function and exacerbates cardiovascular disease processes. Because of their effectiveness

in hypertension and beneficial effects on the heart, blood vessels, and kidneys, these drugs are increasing in importance, number, and use. Widely used to treat heart failure and hypertension, the drugs may also decrease morbidity and mortality in other cardiovascular disorders. They improve post–myocardial infarction survival when added to standard therapy of aspirin, a beta blocker, and a thrombolytic.

 

ACE inhibitors may be used alone or in combination with other antihypertensive agents, such as thiazide diuretics. Although the drugs can cause or aggravate proteinuria and renal damage iondiabetic people, they decrease proteinuria and slow the development of nephropathy in diabetic clients.

Most ACE inhibitors (captopril, enalapril, fosinopril, lisinopril, ramipril, and quinapril) also are used in the management of heart failure because they decrease peripheral vascular resistance, cardiac workload, and ventricular remodeling. Captopril and other ACE inhibitors are recommended as first-line agents for treating hypertension in diabetic clients, particularly those with type 1 diabetes and/or diabetic nephropathy, because they reduce proteinuria and slow progression of renal impairment.

ACE inhibitors are well absorbed with oral administration, produce effects within 1 hour that last approximately 24 hours, have prolonged serum half-lives with impaired renal function, and most are metabolized to active metabolites that are excreted in urine and feces. These drugs are well tolerated, with a low incidence of serious adverse effects (eg, neutropenia, agranulocytosis, proteinuria, glomerulonephritis, and angioedema). However, a persistent cough develops in approximately 10% to 20% of clients and may lead to stopping the drug. Also, acute hypotension may occur when an ACE inhibitor is started, especially in clients with fluid volume deficit. This reaction may be prevented by starting with a low dose, taken at bedtime, or by stopping diuretics and reducing dosage of other antihypertensive drugs temporarily. Hyperkalemia may develop in clients who have diabetes mellitus or renal impairment or who are taking nonsteroidal anti-inflammatory drugs, potassium supplements, or potassium-sparing diuretics.

These drugs are contraindicated during pregnancy because serious illnesses, including renal failure, have occurred ieonates whose mothers took an ACE inhibitor during the second and third trimesters.

 

         The angiotensin-converting enzyme (ACE) inhibitors (captopril, enalapril, lisinopril) are recommended when  the preferred first-line agents (diuretics or b-blockers) are  contraindicated or ineffective. Despite their wide-spread use, it is not clear if antihypertensive therapy with ACE inhibitors increases the risk of other major diseases.

 

 

        

Actions. The ACE inhibitors lower blood pressure by reducing peripheral  vascular resistance without reflexly increasing cardiac  output, rate, or contractility.  These drugs block the angiotensin converting enzyme  that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II. Vasodilation occurs as a result of the combined effects of lower vasoconstriction  caused by diminished levels of angiotensin II and the potent vasodilating  effect of  increased bradykinin.  By reducing circulating angiotensin II levels, ACE inhibitors also  decreas the secretion of aldosterone, resulting in decreased sodium and water retention.

         Like b-blockers, ACE inhibitors are most effective in hypertensive  patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike b-blockers, ACE inhibitors are effective in the management of patients with  chronic  congestive heart  failure.  ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started  24 hours after the end of the infarction.

 

         Adverse  effects. Common side effects include dry cough, rashes, fever, altered taste, hypotension, and hyperkalemia. Potassium levels must be monitored, and potassium supplements or spironolactone  are contraindicated. Because of the risk of angioedema and first dose syncope, ACE inhibitors are first administered in the physician’s office with close observation. Reversible  renal failure can occur in patients with severe renal artery stenosis. ACE inhibitors are fetotoxic and should not be used in pregnant women.

ANGIOTENSIN II ANTAGONISTS.

 

         Angiotensin II receptor blockers (ARBs) were developed to block the strong blood pressure–raising effects of angiotensin II. Instead of decreasing production of angiotensin II, as the ACE inhibitors do, these drugs compete with angiotensin II for tissue binding sites and prevent angiotensin II from combining with its receptors in body tissues. Although multiple types of receptors have been identified, the AT1 receptors located in brain, renal, myocardial, vascular, and adrenal tissue determine most of the effects of angiotensin II on cardiovascular and renal functions. ARBs block the angiotensin II AT1 receptors and decrease arterial blood pressure by decreasing systemic vascular resistance .

These drugs are similar to ACE inhibitors in their effects on blood pressure and hemodynamics and are as effective as ACE inhibitors in the management of hypertension and probably heart failure. They are less likely to cause hyperkalemia than ACE inhibitors, and the occurrence of a persistent cough is rare. Overall, the drugs are well tolerated, and the incidence of most adverse effects is similar to that of placebo.

Losartan, the first ARB, is readily absorbed and rapidly metabolized by the cytochrome P450 liver enzymes to an active metabolite. Both losartan and the metabolite are highly bound to plasma albumin, and losartan has a shorter duration of action than its metabolite. When losartan therapy is started, maximal effects on blood pressure usually occur within 3 to weeks. If losartan alone does not control blood pressure, a low dose of a diuretic may be added. A combination product of losartan and hydrochlorothiazide is available.

 

         The nanopeptide losartan, a highly selective angiotensin II receptor blocker, has recently been approved for antihypertensive therapy. Its  pharmacologic effects are similar to ACE inhibitors in that it produces vasodilation and blocks aldosterone secretion. Its adverse effects is improved over the ACE  inhibitors, although it is fetotoxic.

 

 

         CALCIUM CHANNEL BLOCKERS.

Most of the available drugs are approved for use in hypertension. Nifedipine, a short-acting calcium channel blocker, has been used to treat hypertensive emergencies or urgencies, often by puncturing the capsule and squeezing the contents under the tongue or having the client bite and swallow the capsule. Such use is no longer recommended, because this practice is associated with an increased risk of adverse cardiovascular events precipitated by rapid and severe decrease in blood pressure.

As a group, the calcium channel blockers are well absorbed from the gastrointestinal tract following oral administration and are highly bound to protein. The drugs are metabolized in the liver and excreted in urine.

         Calcium channel blockers are recommended when the preferred first-line agents are contraindicated or ineffective. Despite their wide-spread use, it is not clear what effects  antihypertensive therapy with these drugs has  on major disease. In  hypertensive patients use of short-acting calcium channel blockers, especially in high doses, is associated  with  an increased  risk of myocardial infarction.

         

The calcium channel blockers are divided into three chemical classes, each with different  pharmacokinetic properties  and clinical indications.

1.     Diphenylalkylamines. Verapamil is the least selective of any calcium channel blocker, and has significant effects on both  cardiac and smooth-muscle cells. It is used to treat angina, supraventricular tachyarrhythmias, and migrane headache.

2.     Benzothiazepines. Diltiazem affects both  cardiac and vascular smooth-muscle cells; however, it has a less pronounced negative inotropic effect on the heart than does verapamil. 

3.     Dihydropyridines. This rapidly expanding class of calcium channel blockers includes the first-generation nifedipine, and new agents  foe treating cardiovascular disease: amlodipine, felodipine, isradipine, nicardipine and nisoldipine. All the dihydropyridines have a much greater affinity for vascular  calcium channels than for calcium channels in the heart. They are therefore particularly attractive in treating hypertension.

 

Calcium channel antagonists block the  inward movement of calcium by binding to L-tipe calcium channels in the heart and in the smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles.

Calcium channel blockers have an intrinsic natriuretic ; therefore, they do not usually require the addition of a diuretic.  These agents  are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease.

Adverse effects. Although infrequent, side effects include constipation in 10 % of patients, dizziness, headache, and a feeling of fatigue caused by a decrease in blood pressure. Verapamil should be avoid in treating patients with congestive heart failure due to its negative inotropic effects.

 

a-ADRENERGIC BLOCKING AGENTS.

Prazosin, doxazosin and terazosin produce a competitive block of a1 adrenoreceptors. They decrease peripheral vascular resistance and lower arterial  blood pressure by causing the relaxation of  both arterial and venous smooth muscle. These drugs cause only minimal changes in cardiac   output, renal blood flow, and glomerular filtration rate. Postural  hypotension may occur in some  individuals.  Prazosin is used  to treat mild  to moderate hypertension  and is prescribed in combination with propranolol or a diuretic for additive effects.

 

 

CENTRALLY-ACTING ADRENERGIC DRUGS

Clonidinea2-agonist – diminishes central adrenergic outflow. Clonidine does not decrease renal blood flow or glomerular filtration and therefore is useful in the treatment  of hypertension complicated by renal disease. Because it causes sodium and water retention, clonidine is usually administered in combination witj diuretic. Adverse effects are generally mild, but the drug can produce sedation and drying of nasal mucosa. Rebound hypertension occurs following  abrupt withdrawal of clonidine. The drug therefore should be withdrawal slowly if the clinician wishes to change agents.

a-Methyldopa. This a2-agonist  is converted to methylnorepinephrine centrally to diminish the adrenergic outflow from the CNS, leading to reduced total peripheral resistance and  a decreased blood pressure. Because blood flow to the kidmey  is not diminished by its use, a-methyldopa is especially valuable in treating hypertensive patients with renal insufficiency. The most common side effects of a-methyldopa are sedation and drowsiness.

VASODILATORS. The direct-acting smooth muscle relaxants, such as hydralazine and minoxidil, have traditionally not been used as primary drugs to treat hypertension. They  act by producing relaxation of vascular  smooth muscle, which decreases resistance and therefore decreases blood pressure. These agents produce reflex stimulation of the heart. They may prompt   angina pectoris, myocardial infarction, or cardiac  failure in predisposed individuals.

Hydralazine. This drug causes direct vasodilation, acting primarily  on arteries and arterioles.  Hydralazine is used  to treat moderately  severe hypertension. It is almost always administered in  combination with a b-blocker such as propranolol (to balance the reflex tachycardia) and a diuretic (to decrease sodium retention).  Adverse effects of hydralazine  therapy include headache, nausea, sweating, arrhythmia, and precipitation of angina. A lupus-like syndrome can occur with high dosage, but it is reversible on discontinuation of the drug.

Minoxidil. This drug  causes dilation of resistance vessels (arterioles) but not of capacitance vessels (venules). It is administered orally for treatment of severe to malignant hypertension that is  refractory to other drugs.  Reflex tachycardia may be severe and may require the  concomitant use of a diuretic and a b-blocker. Minoxidil causes serious sodium and water retention, leading to volume overload, edema, and congestive heart failure. 

 

PRINCIPLES OF THERAPY

Therapeutic Regimens

Once the diagnosis of hypertension is established, a therapeutic regimen must be designed and implemented. The goal of management for most clients is to achieve and maintaiormal blood pressure range (below 140/90 mm Hg). If this goal cannot be achieved, lowering blood pressure to any extent is still considered beneficial in decreasing the incidence of coronary artery disease and stroke.

The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends a management algorithm in which initial interventions are lifestyle modifications (ie, reduction of weight and sodium intake, regular physical activity, moderate alcohol intake, and no smoking). If these modifications do not produce goal blood pressure or substantial progress toward goal blood pressure within 3 to 6 months, antihypertensive drug therapy should be initiated and the lifestyle modifications should be continued. Although the Committee recommends monotherapy (use of one antihypertensive drug) with a diuretic or a beta blocker because research studies demonstrate reduced morbidity and mortality with these agents, a drug from another classification (eg, ACE inhibitors, ARBs, calcium channel blockers, alpha1-adrenergic blockers) may also be used effectively. Studies also indicate decreased cardiovascular morbidity and mortality with ACE inhibitors.

If the initial drug (and dose) does not produce the desired blood pressure, options for further management include increasing the drug dose, substituting another drug, or adding a second drug from a different group. If the response is still inadequate, a second or third drug may be added, including a diuretic if not previously prescribed. When current management is ineffective, reassess the client’s compliance with lifestyle modifications and drug therapy. In addition, review other factors that may decrease the therapeutic response,such as over-the-counter appetite suppressants, dietary or herbal supplements, or nasal decongestants, which raise blood pressure.

The World Health Organization and the International Society of Hypertension guidelines for management of hypertension include considering age, ethnicity, and concomitant cardiovascular disorders when choosing an antihypertensive drug; starting with a single drug, in the lowest available dose; changing to a drug from a different group, rather than increasing dosage of the first drug or adding a second drug, if the initial drug is ineffective or not well tolerated; and using long-acting drugs (ie, a single dose effective for 24 hours). The guidelines also note that many clients require two or more drugs to achieve adequate blood pressure control. When this is the case, fixed-dose combinations or long-acting agents may be preferred, as they decrease the number of drugs and doses that are required and may increase compliance.

 

 

References

1.     Bhatt AB, Stone PH: Current strategies for the prevention of angina in patients with stable coronary artery disease. Curr Opin Cardiol 2006;21:492. [PMID: 16900014]

2.     Borer JS: Clinical effect of ‘pure’ heart rate slowing with a prototype If inhibitor: placebo-controlled experience with ivabradine. Adv Cardiol 2006;43:54. [PMID: 16936472]

3.     Braunwald E et al: ACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002. Circulation 2002;106:1893. [PMID: 12356647]

4.     Carmichael P, Lieben J: Sudden death in explosives workers. Arch Environ Health 1963;7:50.

5.     Chaitman BR: Efficacy and safety of a metabolic modulator drug in chronic stable angina: Review of evidence from clinical trials. J Cardiovasc Pharmacol Ther 2004;9(Suppl 1):S47.

6.     Chaitman BR et al: Effects of ranolazine, with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with sever chronic angina. A randomized controlled trial. JAMA 2004;291:309. [PMID: 14734593]

7.     DeWitt CR, Waksman JC: Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev 2004;23:223. [PMID: 15898828]

8.     Galie N et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148. [PMID: 16291984]

9.     Gibbons RJ et al: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003;41:159. [PMID: 12570960]

10. Ignarro LJ et al: Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside, and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739. [PMID: 6115052]

11. Lacinova L: Voltage-dependent calcium channels. Gen Physiol Biophys 2005;24(Suppl 1):1.

12. Peng J, Li Y-J: New insights into nitroglycerin effects and tolerance: Role of calcitonin gene-related peptide. Eur J Pharmacol 2008;586:9. [PMID: 18367169]

13. Pollack CV, Braunwald E: 2007 Update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Implications for emergency department practice. Ann Emerg Med 2008;51:591. [PMID: 18037193]

14. Saint DA: The cardiac persistent sodium current: An appealing therapeutic target? Br J Pharmacol 2008;153:1133. [PMID: 18071303]

15. Triggle DJ: Calcium channel antagonists: clinical uses—past, present and future. Biochem Pharmacol 2007;74:1. [PMID: 17276408]

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Приєднуйся до нас!
Підписатись на новини:
Наші соц мережі